- Conditions
- SCD With Severe Phenotype (HbSS, HbSβ0 Thalassemia, HbSOARab)
- Interventions
- Quantitative sensory testing
- Other
- Lead sponsor
- Julia Finkel
- Other
- Eligibility
- 13 Years to 30 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss, Hbsc, Sickle Beta Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Syndrome Variant
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia
- Interventions
- Hydroxyurea
- Drug
- Lead sponsor
- Lifespan
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Atlanta, Georgia • Peoria, Illinois + 9 more
- Conditions
- Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Albuminuria
- Interventions
- Empagliflozin (oral)
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sickle Cell Disease
- Interventions
- IMR-687, Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 7
- States / cities
- Oakland, California • Farmington, Connecticut • Hollywood, Florida + 3 more
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Beta-Thalassemia, Transfusion Dependent Beta-Thalassaemia
- Interventions
- autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452
- Biological · Device
- Lead sponsor
- Daniel Bauer
- Other
- Eligibility
- 13 Years to 40 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
- Interventions
- Montelukast added to Hydroxyurea, Placebo added to Hydroxyurea
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • Milwaukee, Wisconsin
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia in Children, Sickle Cell Disease (SCD), Sickle Cell, Sickle Cell Anemia (HbSS)
- Interventions
- Individuation and Perspective-Taking (IPT), pediatric SCD pain management education session
- Behavioral · Other
- Lead sponsor
- Connecticut Children's Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)
- Interventions
- PK-optimized oral hydroxyurea at MTD until 15 years of age.
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Sickle Cell Disease
- Interventions
- IMR-687
- Drug
- Lead sponsor
- Imara, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Farmington, Connecticut • Hollywood, Florida • Temple, Texas
- Conditions
- Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
- Interventions
- Hemanext ONE System, Conventional RBCs
- Device
- Lead sponsor
- Hemanext
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Farmington, Connecticut • St. Petersburg, Florida • Atlanta, Georgia + 2 more